Frank joined the Wyss Institute in 2014 and is working on start-up opportunities in the biotechnology area. Prior, he held CEO positions in various biotechnology companies, including Seres Health, a human microbiome company founded by Flagship Ventures, SpringLeaf Therapeutics, a drug – device combination product company spun out of MIT and BioAxone Therapeutic, Inc., a clinical stage spinal cord injury company based in Montreal, Canada. From 1995 to March 2005, Frank was employed by Novartis AG where he held various leadership roles, including General Manager and Country Head of Novartis South Korea and General Manager of Novartis Vietnam. Frank has a BSc in Chemistry from the University of Bielefeld, Germany and a Ph.D. in Bio-organic Chemistry from the University of California at Davis. He was a Postdoctoral Research Fellow in biochemistry in the laboratory of Nobel Laureate Prof. Bruce Merrifield, Rockefeller University, New York and earned an M.B.A. from INSEAD in Fontainebleau, France.